Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “PDL1 CPS < 5”

5 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 5 of 5 results

Testing effectiveness (Phase 2)Study completedNCT05299476
What this trial is testing

CAPOX + Bevacizumab + Tislelizumab Treating PD-L1 CPS < 5 Locally Advanced or Metastatic GEA

Who this might be right for
Advanced Gastroesophageal AdenocarcinomaFirst-line TherapyPDL1 CPS < 5
Chinese PLA General Hospital 32
Not applicableActive Not RecruitingNCT05165264
What this trial is testing

Nivolumab Plus Chemotherapy in First Line Treatment of Adult Participants With Advanced or Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
Bristol-Myers Squibb 600
Large-scale testing (Phase 3)Not Yet RecruitingNCT07716449
What this trial is testing

QLS31905 in Combination With CAPOX Versus Sintilimab in Combination With CAPOX as First-line Treatment in Patients With GC/GEJ

Who this might be right for
Gastric or Gastroesophageal Junction Adenocarcinoma
Qilu Pharmaceutical Co., Ltd. 560
Testing effectiveness (Phase 2)Looking for participantsNCT06253611
What this trial is testing

First-line EXL01 With Nivolumab and FOLFOX for PD-L1 CPS ≥5 Metastatic Gastric Cancer

Who this might be right for
Gastric Cancer
GERCOR - Multidisciplinary Oncology Cooperative Group 120
Large-scale testing (Phase 3)Looking for participantsNCT06177041
What this trial is testing

M108 Plus CAPOX Versus Placebo Plus CAPOX as First-line Treatment for Claudin (CLDN) 18.2-Positive, HER2-Negative, PD-L1 CPS<5, Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma.

Who this might be right for
Locally Advanced Unresectable or Metastatic Gastric CancerLocally Advanced Unresectable or Metastatic Gastroesophageal Junction (GEJ) Adenocarcinoma
FutureGen Biopharmaceutical (Beijing) Co., Ltd 486